Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis

Oncogene

Volumn 30, Issue 8, 2011, Pages 896-906

  Li, J ^a   Cheng, Y ^a   Tai, D ^a   Martinka, M ^a   Welch, D R ^b   Li, G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b University of Alabama at Birmingham   (United States)

Author keywords

angiogenesis; BRMS1; melanoma; prognosis; tumor progression

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER METASTASIS SUPPRESSOR 1 GENE; CANCER GROWTH; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DYSPLASTIC NEVUS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC PREDISPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; SKIN MELANOMA; STAINING; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE;

ANIMALS; BLOTTING, WESTERN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MELANOMA; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

MUS MUSCULUS;

EID: 79952002262     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.470     Document Type: Article

References (52)

1. Angeletti CA, Lucchi M, Fontanini G, Mussi A, Chella A, Ribechini A et al. (1996). Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer 78: 409-415.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al. (2001). Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635-3648. (Pubitemid 32786276)
3. Ballo MT, Ang KK. (2003). Radiation therapy for malignant melanoma. Surg Clin North Am 83: 323-342. (Pubitemid 36514812)
4. Brawer MK. (1996). Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument for. Eur Urol 29(Suppl 2): 19-23.
5. Cicek M, Fukuyama R, Cicek MS, Sizemore S, Welch DR, Sizemore N et al. (2009). BRMS1 contributes to the negative regulation of uPA gene expression through recruitment of HDAC1 to the NF-kappaB binding site of the uPA promoter. Clin Exp Metastasis 26: 229-237.
6. Cicek M, Fukuyama R, Welch DR, Sizemore N, Casey G. (2005). Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 65: 3586-3595. (Pubitemid 40616334)
7. Czubayko F, Schulte AM, Berchem GJ, Wellstein A. (1996). Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci USA 93: 14753-14758. (Pubitemid 26419041)
8. Dai DL, Martinka M, Li G. (2005). Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23: 1473-1482.
9. Dai J, Peng L, Fan K, Wang H, Wei R, Ji G et al. (2009). Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28: 3412-3422.
10. Dauda MM, Shehu SM. (2005). Malignant melanoma: a review. Niger Postgrad Med J 12: 125-130.
11. Diao H, Kon S, Iwabuchi K, Kimura C, Morimoto J, Ito D et al. (2004). Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21: 539-550. (Pubitemid 39370509)
12. Folkman J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
13. Garate M, Campos EI, Bush JA, Xiao H, Li G. (2007). Phosphorylation of the tumor suppressor p33(ING1b) at Ser-126 influences its protein stability and proliferation of melanoma cells. Faseb J 21: 3705-3716. (Pubitemid 350075158)
14. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M et al. (1993). Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55: 739-744. (Pubitemid 23354886)
15. Grossman D, Altieri DC. (2001). Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20: 3-11. (Pubitemid 34074673)
16. Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, Postenka CO et al. (2008). Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer 123: 526-534. (Pubitemid 351898409)
17. Hersey P. (2003). Adjuvant therapy for high-risk primary and resected metastatic melanoma. Intern Med J 33: 33-43.
18. Hicks DG, Yoder BJ, Short S, Tarr S, Prescott N, Crowe JP et al. (2006). Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res 12: 6702-6708. (Pubitemid 44876838)
19. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML,Merino MJ. (1995). Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147: 33-41.
20. Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 69: 1279-1283.
21. Karst AM, Gao K, Nelson CC, Li G. (2009). Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 124: 494-501.
22. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. (2003). Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J Urol 169: 1122-1133. (Pubitemid 36188186)
23. Li G, Tang L, Zhou X, Tron V, Ho V. (1998). Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 8: 17-23. (Pubitemid 28114297)
24. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T et al. (1995). Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 72: 319-323.
25. Maffey AH, Ishibashi T, He C, Wang X, White AR, Hendy SC et al. (2007). Probasin promoter assembles into a strongly positioned nucleosome that permits androgen receptor binding. Mol Cell Endocrinol 268: 10-19. (Pubitemid 46437350)
26. Mansfield PF, Lee JE, Balch CM. (1994). Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 31: 253-374.
27. Meehan WJ, Samant RS, Hopper JE, Carrozza MJ, Shevde LA, Workman JL et al. (2004). Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 279: 1562-1569. (Pubitemid 38082687)
28. Meehan WJ, Welch DR. (2003). Breast cancer metastasis suppressor 1: update. Clin Exp Metastasis 20: 45-50. (Pubitemid 36308135)
29. Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS et al. (2008). Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer. Clin Exp Metastasis 25: 753-763.
30. Ostmeier H, Fuchs B, Otto F, Mawick R, Lippold A, Krieg V et al. (1999). Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 85: 2391-2399.
31. Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR. (2008). BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 172: 809-817. (Pubitemid 351354552)
32. Remmele W, Stegner HE. (1987). Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140.
33. Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH et al. (2007). Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 6: 6.
34. Samant RS, Seraj MJ, Saunders MM, Sakamaki TS, Shevde LA, Harms JF et al. (2000). Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 18: 683-693.
35. Seraj MJ, Harding MA, Gildea JJ, Welch DR, Theodorescu D. (2000a). The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin Exp Metastasis 18: 519-525. (Pubitemid 32844253)
36. Seraj MJ, Samant RS, Verderame MF, Welch DR. (2000b). Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 60: 2764-2769. (Pubitemid 30395788)
37. Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ et al. (2002). Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 273: 229-239. (Pubitemid 34920673)
38. Soengas MS, Lowe SW. (2003). Apoptosis and melanoma chemoresistance. Oncogene 22: 3138-3151. (Pubitemid 36713766)
39. Standal T, Borset M, Sundan A. (2004). Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179-184.
40. Struhl K. (1995). Yeast transcriptional regulatory mechanisms. Annu Rev Genet 29: 651-674.
41. Thompson JF, Scolyer RA, Kefford RF. (2005). Cutaneous melanoma. Lancet 365: 687-701. (Pubitemid 40260892)
42. Tsao H, Sober AJ. (2005). Melanoma treatment update. Dermatol Clin 23: 323-333.
43. Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG et al. (2008). Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem 283: 28354-28360.
44. Weidner N. (1995). Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147: 9-19.
45. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. (1993). Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409. (Pubitemid 24058195)
46. Weidner N, Semple JP, Welch WR, Folkman J. (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.
47. Welch DR, Goldberg SF. (1997). Molecular mechanisms controlling human melanoma progression and metastasis. Pathobiology 65: 311-330. (Pubitemid 28041158)
48. Wiggins DL, Granai CO, Steinhoff MM, Calabresi P. (1995). Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecol Oncol 56: 353-356.
49. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S et al. (1994). Tumor angiogenesis in human lung adenocarcinoma. Cancer 74: 2245-2250. (Pubitemid 24322278)
50. Yang J, Zhang B, Lin Y, Yang Y, Liu X, Lu F. (2008). Breast cancer metastasis suppressor 1 inhibits SDF-1alpha-induced migration of non-small cell lung cancer by decreasing CXCR4 expression. Cancer Lett 269: 46-56.
51. Zainabadi K, Benyamini P, Chakrabarti R, Veena MS, Chandrasekharappa SC, Gatti RA et al. (2005). A 700-kb physical and transcription map of the cervical cancer tumor suppressor gene locus on chromosome 11q13. Genomics 85: 704-714. (Pubitemid 40693358)
52. Zhang S, Lin QD, Di W. (2006). Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 16: 522-531.